Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Envafolimab (Primary) ; YH 001 (Primary)
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TRACON Pharmaceuticals

    • Most Recent Events

    • 19 Sep 2023 Status changed from recruiting to active, no longer recruiting.
    • 20 Jun 2023 According to Tracon Pharmaceuticals media release, Company expects to report trial data at the Connective Tissue Oncology Society (CTOS) annual meeting in November
    • 10 May 2023 According to a TRACON Pharmaceuticals media release, data from this trial is expected in the second half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top